Cholesterol feeding accentuates the cyclosporine-induced elevation of renal plasminogen activator inhibitor type 1.
暂无分享,去创建一个
[1] W. Bennett,et al. Chronic cyclosporine nephrotoxicity , 1998, Current opinion in nephrology and hypertension.
[2] A. Eddy. Interstitial inflammation and fibrosis in rats with diet-induced hypercholesterolemia. , 1996, Kidney international.
[3] A. Eddy. Expression of genes that promote renal interstitial fibrosis in rats with proteinuria. , 1996, Kidney international. Supplement.
[4] W. Bennett,et al. Role of transforming growth factor-beta 1 in experimental chronic cyclosporine nephropathy. , 1996, Kidney international.
[5] L. V. Van Gaal,et al. Elevated plasminogen activator inhibitor levels in cyclosporin-treated renal allograft recipients. , 1996, Nephrology, Dialysis and Transplantation.
[6] P. Declerck,et al. Characterization of common neoantigenic epitopes generated in plasminogen activator inhibitor‐1 after cleavage of the reactive center loop or after complex formation with various serine proteinases , 1995, FEBS letters.
[7] M. Bally,et al. LIPOSOMAL CYCLOSPORINE: COMPARISON OF DRUG AND LIPID CARRIER PHARMACOKINETICS AND BIODISTRIBUTION , 1995, Transplantation.
[8] J. Barnes,et al. Expression of plasminogen activator-inhibitor-1 (PAI-1) during cellular remodeling in proliferative glomerulonephritis in the rat. , 1995, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[9] C. Alpers,et al. Cellular proliferation and macrophage influx precede interstitial fibrosis in cyclosporine nephrotoxicity. , 1995, Kidney international.
[10] M. Robertson,et al. Oxidation of low density lipoproteins from patients with renal failure or renal transplants. , 1995, Kidney international.
[11] A. Eddy,et al. Renal expression of genes that promote interstitial inflammation and fibrosis in rats with protein-overload proteinuria. , 1995, Kidney international.
[12] T. Hammond,et al. Segmental distribution of the endocytosis receptor gp330 in renal proximal tubules. , 1995, European journal of cell biology.
[13] J. Horton,et al. Regulation of Hepatic 7α-Hydroxylase Expression and Response to Dietary Cholesterol in the Rat and Hamster (*) , 1995, The Journal of Biological Chemistry.
[14] R. Chalmers,et al. Effect of low-dose cyclosporin on plasma lipoproteins and markers of cholestasis in patients with psoriasis. , 1995, QJM : monthly journal of the Association of Physicians.
[15] R. Atkins,et al. A novel, simple, reliable, and sensitive method for multiple immunoenzyme staining: use of microwave oven heating to block antibody crossreactivity and retrieve antigens. , 1995, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[16] D. Sgoutas,et al. CYCLOSPORINE INCREASES THE OXIDIZABILITY OF LOW‐DENSITY LIPOPROTEINS IN RENAL TRANSPLANT RECIPIENTS , 1994, Transplantation.
[17] K. Rentsch,et al. Relation of cyclosporine blood levels to adverse effects on lipoproteins. , 1994, Transplantation.
[18] E. Emeson,et al. Accelerated atherosclerosis in hyperlipidemic C57BL/6 mice treated with cyclosporin A. , 1993, The American journal of pathology.
[19] E. Vilella,et al. Low-density lipoprotein metabolism in rats treated with cyclosporine. , 1993, Metabolism: clinical and experimental.
[20] Yufei Wang,et al. Expression and localization of plasminogen activator inhibitor 1 mRNA in transplant kidneys , 1993, The Journal of pathology.
[21] E. Tremoli,et al. Increased synthesis of plasminogen activator inhibitor-1 by cultured human endothelial cells exposed to native and modified LDLs. An LDL receptor-independent phenomenon. , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.
[22] D. Steinberg,et al. Role of oxidized low density lipoprotein in atherogenesis. , 1991, The Journal of clinical investigation.
[23] Y. Eguchi,et al. Cellular localization of type 1 plasminogen activator inhibitor messenger RNA and protein in murine renal tissue. , 1993, The American journal of pathology.
[24] W. Border,et al. Glomerular matrix accumulation is linked to inhibition of the plasmin protease system. , 1992, Kidney international.
[25] H. Büller,et al. IMPAIRED FIBRINOLYSIS IN CYCLOSPORINE‐TREATED RENAL TRANSPLANT PATIENTS ANALYSIS OF THE DEFECT AND BENEFICIAL EFFECT OF FISH‐OIL , 1992, Transplantation.
[26] S. Moestrup,et al. Purified alpha 2-macroglobulin receptor/LDL receptor-related protein binds urokinase.plasminogen activator inhibitor type-1 complex. Evidence that the alpha 2-macroglobulin receptor mediates cellular degradation of urokinase receptor-bound complexes. , 1992, The Journal of biological chemistry.
[27] R. Wood,et al. Proliferating cell nuclear antigen is required for DNA excision repair , 1992, Cell.
[28] K. Okada,et al. Tissue‐type plasminogen activator and its inhibitor in human glomerulonephritis , 1992, The Journal of pathology.
[29] M. Seed,et al. Lipid and lipoprotein (a) concentrations in renal ransplant patients , 1992 .
[30] M. Scully. PLASMINOGEN ACTIVATOR‐DEPENDENT PERICELLULAR PROTEOLYSIS , 1991, British journal of haematology.
[31] D. Belin,et al. The plasminogen activator/plasmin system. , 1991, The Journal of clinical investigation.
[32] B. Lacour,et al. Atherosclerosis and lipid disorders after renal transplantation. , 1991, Kidney international. Supplement.
[33] P. Hylemon,et al. Regulation of bile acid synthesis , 1991, Hepatology.
[34] K. Preissner,et al. Structure and biological role of vitronectin. , 1991, Annual review of cell biology.
[35] V. Kliem,et al. Impact of long-term immunosuppression with cyclosporin A on serum lipids in stable renal transplant recipients , 1991, Transplant international : official journal of the European Society for Organ Transplantation.
[36] E. Kovacs. Fibrogenic cytokines: the role of immune mediators in the development of scar tissue. , 1991, Immunology today.
[37] H. Aynedjian,et al. Renal vasoconstriction caused by short-term cholesterol feeding is corrected by thromboxane antagonist or probucol. , 1990, The Journal of clinical investigation.
[38] A. Hamsten,et al. Secretion of plasminogen activator inhibitor-1 from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein. , 1990, Arteriosclerosis.
[39] P. Klotman,et al. Cellular and molecular mechanisms of cyclosporin nephrotoxicity. , 1990, Journal of the American Society of Nephrology : JASN.
[40] E. Kruithof,et al. Plasminogen activator inhibitor 1 in renal fibrin deposits of human nephropathies. , 1990, Clinical nephrology.
[41] M. Brezis,et al. Chronic cyclosporine-induced nephropathy in the rat. A medullary ray and inner stripe injury. , 1990, Transplantation.
[42] A. Gotto,et al. Effects of cyclosporine therapy on plasma lipoprotein levels. , 1989, JAMA.
[43] Rochelle L. Garcia,et al. Analysis of proliferative grade using anti-PCNA/cyclin monoclonal antibodies in fixed, embedded tissues. Comparison with flow cytometric analysis. , 1989, The American journal of pathology.
[44] L. Truong,et al. CHRONIC CYCLOSPORINE NEPHROTOXICITY A RODENT MODEL , 1988, Transplantation.
[45] H. Starklint,et al. Cyclosporine A in high dosages induces renal interstitial fibrosis in the rat. , 1988, Transplantation proceedings.
[46] J. Mann,et al. Adverse effect of cyclosporin on plasma cholesterol in renal transplant recipients. , 1988, Nephrology, Dialysis and Transplantation.
[47] M. Alessi,et al. Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. , 1988, Blood.
[48] C. Hsu,et al. Alterations in renal structure and function in a rat model of cyclosporine nephrotoxicity. , 1987, The Journal of pharmacology and experimental therapeutics.
[49] R. Lebo,et al. cDNA cloning of human plasminogen activator-inhibitor from endothelial cells. , 1986, The Journal of clinical investigation.
[50] L. Racusen,et al. Acute renal failure produced by combining cyclosporine and brief renal ischemia in the Munich Wistar rat. , 1986, Clinical nephrology.
[51] W. Bennett,et al. Action and toxicity of cyclosporine. , 1986, Annual review of medicine.
[52] F. Roels,et al. Cyclosporine nephrotoxicity: comparative cytochemical study of rat kidney and human allograft biopsies. , 1986, Clinical nephrology.
[53] D. Loskutoff,et al. Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants. , 1985, The Journal of biological chemistry.
[54] E. Döpp,et al. The heterogeneity of mononuclear phagocytes in lymphoid organs: distinct macrophage subpopulations in rat recognized by monoclonal antibodies ED1, ED2 and ED3. , 1985, Advances in experimental medicine and biology.
[55] A. Barclay,et al. Molecular and antigenic heterogeneity of the rat leukocyte‐common antigen from thymocytes and T and B lymphocytes , 1985, European journal of immunology.
[56] H. Wilczek,et al. INTERSTITIAL FIBROSIS IN RENAL ALLOGRAFTS AFTER 12 TO 46 MONTHS OF CYCLOSPORIN TREATMENT: BENEFICIAL EFFECT OF LOW DOSES IN EARLY POST-TRANSPLANTATION PERIOD , 1984, The Lancet.
[57] A. Smith,et al. The effect of salt intake on cyclosporine-induced impairment of renal function in rats. , 1984, Transplantation.
[58] B. Myers,et al. Cyclosporine-associated chronic nephropathy. , 1984, The New England journal of medicine.
[59] A. Thomson,et al. Enhancement of high dose cyclosporin A toxicity by frusemide. , 1984, Biochemical pharmacology.
[60] W. McMaster,et al. Two subsets of rat T lymphocytes defined with monoclonal antibodies , 1980, European journal of immunology.
[61] W. McMaster,et al. Identification of Ia glycoproteins in rat thymus and purification from rat spleen , 1979, European journal of immunology.